Diadema Partners’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
Other funds holding RNAC
6CM
Diadema Partners's RNAC Position: Q3 2026 in Review
Diadema Partners sold out of Cartesian Therapeutics (RNAC) in Q3 2026, closing a stake of 87,057 shares — an estimated $907K sold.
Diadema Partners first reported a position in RNAC in Q2 2026 and held it in 1 quarter. The position peaked at $907K in Q2 2026. 99 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.
- Diadema Partners reported no remaining Cartesian Therapeutics position as of Q3 2026 after selling out during the quarter.
- Diadema Partners sold 87,057 Cartesian Therapeutics shares in Q3 2026, an estimated $907K.
- Diadema Partners first reported a position in Cartesian Therapeutics in Q2 2026 and held it in 1 quarter.
- Diadema Partners's Cartesian Therapeutics position peaked at $907K in Q2 2026.
- 99 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.
Based on Diadema Partners's 13F filing for Q3 2026, filed 16 Nov 2026.